Another study by Shi et al. showed that after using CAR-T cell therapy along with anti-CD-19, followed by a maintenance dose of lenalidomide after autologous stem cell transplant for high-risk newly diagnosed MM patients, promising results as well as efficacy were observed. This evidence concerns the gene CD19 and Miyoshi myopathy.